Atria Investments Inc Buys Shares of 4,012 Guardant Health, Inc. $GH

Atria Investments Inc purchased a new position in Guardant Health, Inc. (NASDAQ:GH) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 4,012 shares of the company’s stock, valued at approximately $209,000.

A number of other hedge funds also recently bought and sold shares of GH. Envestnet Asset Management Inc. lifted its holdings in Guardant Health by 136.6% in the first quarter. Envestnet Asset Management Inc. now owns 27,497 shares of the company’s stock valued at $1,171,000 after acquiring an additional 15,877 shares during the period. Cerity Partners LLC increased its position in shares of Guardant Health by 6.4% during the 1st quarter. Cerity Partners LLC now owns 145,475 shares of the company’s stock valued at $6,197,000 after purchasing an additional 8,725 shares during the last quarter. Xponance Inc. lifted its stake in shares of Guardant Health by 6.8% in the 1st quarter. Xponance Inc. now owns 9,116 shares of the company’s stock worth $388,000 after purchasing an additional 582 shares during the period. New York State Common Retirement Fund lifted its stake in shares of Guardant Health by 184.1% in the 1st quarter. New York State Common Retirement Fund now owns 106,884 shares of the company’s stock worth $4,553,000 after purchasing an additional 69,257 shares during the period. Finally, CWM LLC boosted its holdings in shares of Guardant Health by 180.3% in the first quarter. CWM LLC now owns 2,296 shares of the company’s stock worth $98,000 after buying an additional 1,477 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Insider Buying and Selling

In other Guardant Health news, Director Medina Manuel Hidalgo sold 2,165 shares of the company’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $54.16, for a total value of $117,256.40. Following the completion of the transaction, the director directly owned 851 shares in the company, valued at $46,090.16. This represents a 71.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider John G. Saia sold 8,996 shares of Guardant Health stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $96.25, for a total transaction of $865,865.00. Following the sale, the insider owned 43,172 shares in the company, valued at approximately $4,155,305. The trade was a 17.24% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 313,187 shares of company stock valued at $18,993,278. Corporate insiders own 6.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Guggenheim upped their target price on shares of Guardant Health from $56.00 to $67.00 and gave the company a “buy” rating in a report on Thursday, September 25th. Stifel Nicolaus set a $73.00 price objective on Guardant Health in a research note on Thursday, September 25th. Cowen reaffirmed a “buy” rating on shares of Guardant Health in a report on Thursday, October 30th. UBS Group boosted their price target on Guardant Health from $80.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Finally, Raymond James Financial upped their price target on Guardant Health from $59.00 to $61.00 and gave the stock an “outperform” rating in a research report on Thursday, July 31st. Twenty-three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $77.14.

Guardant Health Stock Performance

Shares of Guardant Health stock opened at $94.13 on Friday. Guardant Health, Inc. has a fifty-two week low of $28.45 and a fifty-two week high of $101.57. The company has a market capitalization of $11.86 billion, a P/E ratio of -29.32 and a beta of 1.56. The company has a fifty day moving average of $70.06 and a 200 day moving average of $56.38.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.09. Guardant Health’s revenue was up 38.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.88) earnings per share. Guardant Health has set its FY 2025 guidance at EPS. Analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.